All In MedTech

Device Trial Radar · NCT03150407

Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness

A Pivotal Clinical Investigation to Evaluate the Safety and Efficacy of J3 Bioscience Lubricating Intravaginal Ring VR101 in Relieving Symptoms of Vaginal Dryness

Last checked: Nov 19, 2026Latest source record: Nov 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

72

Actual

Start

May 1, 2017

Primary completion

Aug 31, 2017

Study completion Nov 30, 2017

Sponsor

Lead sponsor
J3 Bioscience, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Advanced Clinical Research Services, LLC; Phil Triolo and Associates LC
First posted
May 12, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This investigation is designed to demonstrate the safety and efficacy of the VR101 lubricating intravaginal ring (IVR) in treating the symptoms of vaginal dryness. In the proposed investigation, participants will use VR101 devices and sham control rings in a crossover study design. All participants who successfully complete the crossover study will be given the option to continue using VR101 for a total of 13 consecutive weeks to evaluate the long-term safety of the new device.

Conditions

  • Menopause Related Conditions
  • Postmenopausal Symptoms

Interventions

  • VR101 Device (Efficacy)Device

    Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days

  • Sham Control RingOther

    Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days

  • VR101 Device (Safety)Device

    Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of VR101 Treatments at 28 Days Assessed by Change in VHI (Vaginal Health Index) Scores Assigned by CliniciansTime frame: Baseline, 28 Days
  2. Serious Adverse Device EffectsTime frame: Up to 24 weeks total, comprising up to 17 weeks total VR101 use and up to 4 weeks total sham control use.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Clinical Research, Inc. (ACR Idaho)

    Meridian, Idaho

  • Advanced Clinical Research, Inc. (ACR Utah)

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.